首页>
外文期刊>Journal of Biosciences and Medicines
>Immunoglobulin G Specific Antibody Level against Ebola Viral Glycoprotein and Nucleoprotein in Ebola Virus Disease Survivors and Their Relatives
【24h】
Immunoglobulin G Specific Antibody Level against Ebola Viral Glycoprotein and Nucleoprotein in Ebola Virus Disease Survivors and Their Relatives
Ebola virus disease is a complex zoonosis that is highly virulent in humans. Despite its sorely pathogenic and lethal nature, survivors of this infection and even asymptomatic cases are able to develop both humoral and cellular immunity against several Ebola virus (EBOV) proteins. We aimed at determining immunoglobulin G (IgG) antibodies level against two Ebola viral antigens, the glycoprotein and the nucleoprotein in Ebola survivors and their relatives. Anti-EBOV glycoprotein (GP) and nucleoprotein (NP) IgG antibodies were quantified using ELISA. We enrolled 199 participants in two different sites as follow: 91 survivors at the Loreto clinic and 70 survivors with 38 relatives of Sierra Leone Association of Ebola Survivors Bombali Branch (SLAESB) tested for anti-EBOV NP and anti-EBOV GP IgG antibodies. Our findings revealed that the median anti-EBOV IgG level among survivors was 5.7128 U/ml [IQR: 2.793 - 7.783] for anti-EBOV GP IgG and 4.431 U/ml [IQR: 2.083 - 7.696] for anti-EBOV NP IgG. Survivors relatives had a median anti-EBOV GP IgG level of ?0.7128 U/ml [IQR: -0.903 to -0.04327] and -2.711 U/ml [IQR: -4.01 to -1.918] for anti-EBOV NP IgG. We observed that IgG levels in survivors were higher than in relatives with a significant difference of about 0.0001. The median value of anti-EBOV IgG level among seropositive relatives was 0.7043 U/ml [IQR: 0.5686 to 3.716] for anti-EBOV GP IgG and 4.05 U/ml [IQR: 0.2765 to 7.759] for anti-EBOV NP IgG respectively. Interestingly, we observed that 3.30% of Loreto clinic survivors did not developed anti-EBOV NP IgG antibodies; also about 10% survivors of the SLAESB were not reactive to anti-EBOV NP IgG and 1.43% of these survivors did not express antibodies against the Ebola viral glycoprotein. Our work is consistent with previous published studies showing heterogeneity in both survivors and asymptomatic cases of Ebola infection developing adaptive immunity against EBOV proteins.
展开▼
机译：埃博拉病毒疾病是一种复杂的人群，对人类具有高毒性。尽管其引起了致病性和致命性，但这种感染的幸存者甚至是无症状的病例都能够对几种埃博拉病毒（EBOV）蛋白质产生体液和细胞免疫力。我们旨在将免疫球蛋白G（IgG）抗体水平与两个埃博拉病毒抗原，糖蛋白和埃博兰幸存者及其亲属中的核蛋白蛋白相提并论。使用ELISA定量抗EBOV糖蛋白（GP）和核蛋白（NP）IgG抗体。我们在两个不同的地点注册了199名参与者，如下所示：91个幸存者诊所和70个幸存者，埃博拉幸存者Bombali枝（SLAESB）的塞拉利沃氏菌塞拉利氏菌属协会的38个亲属进行了抗EBOV NP和抗EBOV GP IgG抗体。我们的研究结果表明，避免者中的中位抗EBOV IgG水平为抗EBOV GP IgG和4.431 U / ML [IQR：2.083 - 7.696]的抗EBOV NP IgG的5.7128 U / mL [IQR：2.793 - 7.783]。幸存者亲属的中值抗EBOV GP IgG水平Δ0.7128u / ml [IQR：-0.903至-0.04327]和-2.711 U / ml [IQR：-4.01至-1.918]用于抗EBOV NP IgG。我们观察到幸存者中IgG水平高于亲属，具有约0.0001的显着差异。对于抗EBOVGP IgG和4.05 U / mL [IQR：0.2765至7.759]，血清阳性亲属抗EBOV IgG水平的中值值分别为抗EBOV NP IgG为0.7043 U / mL [IQR：0.5686至3.716]。有趣的是，我们观察到3.30％的洛雷托临床幸存者没有开发抗EBOV NP IgG抗体; SLAESB的约10％幸存者对抗EBOV NP IgG的反应性没有反应，1.43％的这些幸存者没有表达抗埃博拉病毒糖蛋白的抗体。我们的作品与先前公布的研究一致，显示出幸存者的异质性和埃博拉感染的无症状病例，效应对EBOV蛋白的适应性免疫。
展开▼
